G. Pialoux and J. Chas, Hôpital Tenon, Service Maladies infectieuses et tropicales

U. Inserm, F. L. Sesstim)-marseille, M. Alric-;-hôpital-purpan, . Interne, F. Toulouse et al., Assistance Publique des Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service des maladies infectieuses et tropicales, Unité d'Hépatologie, AP-HP Hôpital Cochin, USM20, Institut Pasteur, Université Paris-Descartes, p.94800, 92296.

L. Piroth-;-dijon, F. A. Simon-;-lyon, and F. E. Billaud, Zucman: Hôpital Foch, unité VIH, Service Médecine interne et immunologie, Clamart 92140, France. P. Miailhes: Service des Maladies Infectieuses et Tropicales

F. G. Strasbourg, ;. Peytavin, C. Petrov-sanchez, and . Cagnot, Clinical Centres (ward / participating physicians): APHP, Hôpitaux Universitaires Paris Centre, Paris (Médecine Interne et Maladies Infectieuses: D. Salmon, R. Usubillaga; Hépatogastro-entérologie: P. Sogni, p.75013

, Maladies Infectieuses et Tropicales: C. Katlama, M.A. Valantin, H. Stitou

:. F. Anatomo-pathologie and . Charlotte, Virologie: S. Fourati

. Aphm-sainte-marguerite,

, Virologie: C. Tamalet)

. Aphp-tenon, . Paris-(maladies-infectieuses, :. G. Tropicales, J. Pialoux, :. P. Chas;-anatomo-pathologie et al.,

, Toulouse (Maladies Infectieuses et Tropicales: B. Marchou; Médeicne interne: L. Alric; Hépato-gastro-entérologie: K. Barange, S. Metivier

, Virologie: F. Larroquette)

, Infectiologie: A. Naqvi, V. Rio; Anatomo-pathologie

. Aphp-avicenne, V. Bobigny-(médecine-interne-unité, :. A. Bouchaud;-anatomo-pathologie, M. Martin, :. Y. Virologie et al.,

H. Joseph-ducuing, ;. M. Uzan, A. Bicart-see, D. Garipuy, and M. J. Ferro-collados,

. Anatomo-pathologie, Virologie: F. Nicot

-. Aphp-bichat,

. Anatomo-pathologie:-h.-adle-biassette, Pharmacologie: G. Peytavin)

;. C. Aphp-saint-louis, J. M. Lascoux-combe, and . Molina, Anatomopathologie: P. Bertheau; Virologie: M.L. Chaix

;. K. Aphp-saint-antoine, J. Lacombe, ;. Bottero, P. M. Krause, . Girard et al., Maladies Infectieuses et Tropicales

H. P. Aphp, . Sud, and P. Bicêtre, Maladies Infectieurses et Tropicales: D. Vittecocq; Médecine Interne

. Aphp-necker, . Paris-(maladies-infectieuses, :. O. Tropicales, C. Lortholary, C. Duvivier et al., Virologie: V. Avettand-Fenoel, E. Gardiennet, A. Mélard

A. Ochoa, E. Blanchard, S. Castet-lafarie, C. Cazanave, D. Malvy et al., Maladies Infectieuses et Tropicales: D. Neau

P. Morlat, D. Lacoste, F. Bonnet, N. Bernard, M. Hessamfar et al., Médecine Interne et Maladies Infectieuses

E. Viallard, C. Lazzaro, :. P. Greib;-anatomo-pathologie, and . Bioulac-sage, Virologie: P. Trimoulet, S. Reigadas

F. Hôpital, :. D. Suresnes-(médecine-interne, C. Zucman, :. M. Majerholc;-virologie, E. Brollo et al.,

. Aphp-antoine-béclère, :. F. Clamart-(médecine-interne, J. Boué, I. Devoto, V. Kansau et al., Virologie: C. Deback)

F. Raffi, C. Allavena, V. Reliquet, D. Boutoille, and C. Biron, Nantes (Maladies Infectieuses et Tropicales: E. Billaud

M. Lefebvre, N. Hall, S. Bouchez;-virologie, :. A. Rodallec, and L. L. Guen, C. Hemon)

. Hôpital-de-la-croix-rousse, Lyon (Maladies Infectieuses et Tropicales: P

D. Miailhes, C. Peyramond, F. Chidiac, F. Ader, A. Biron et al.,

:. J. Hépato-gastro-entérologie, F. Koffi, F. Zoulim, P. Bailly, M. Lack et al., Virologie: C. Scholtes, T.T. Le-Thi

P. Ch-perpignan, Maladies infectieuses et tropicales: H. Aumaître, Virologie: S. Galim)

;. F. Chu-robert-debré, D. Bani-sadr, . Lambert, J. L. Nguyen, M. Berger et al., Médecine interne, maladies infectieuses et immunologie clinique

D. Rey, . Partisani, C. Batard, M. Cheneau, . Priester et al., Management

M. Dequae-merchadou, N. Desvallees, L. Douiri, C. Esterle, R. Gilbert et al.,

L. Platt, P. Easterbrook, E. Gower, B. Mcdonald, K. Sabin et al., Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. The Lancet Infectious diseases, vol.16, pp.485-490, 2016.

M. Chen, W. W. Wong, M. G. Law, S. Kiertiburanakul, E. Yunihastuti et al., Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival, PloS one, vol.11, issue.3, 2016.

H. Kovari, B. Ledergerber, M. Cavassini, J. Ambrosioni, A. Bregenzer et al., High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between, Epub 2015/05/06, vol.63, pp.573-80, 2001.

J. Macias, J. Berenguer, M. A. Japon, J. A. Giron, A. Rivero et al., Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus, Hepatology, vol.50, issue.4, pp.1056-63, 2009.

M. S. Sulkowski, S. H. Mehta, M. S. Torbenson, Y. Higgins, S. C. Brinkley et al., Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults, Aids, vol.21, issue.16, pp.2209-2225, 2007.

M. B. Klein, K. C. Rollet-kurhajec, E. E. Moodie, S. Yaphe, M. Tyndall et al., Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population, 2003.

, Aids, vol.28, issue.13, pp.1957-65, 2014.

P. Morlat, C. Roussillon, S. Henard, D. Salmon, F. Bonnet et al., Causes of death among HIVinfected patients in France in 2010 (national survey): trends since, Aids, vol.28, issue.8, pp.1181-91, 2000.

D. Grint, L. Peters, J. K. Rockstroh, A. Rakmanova, T. Trofimova et al., Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals, Aids, vol.29, issue.10, pp.1205-1220, 2015.

C. J. Smith, L. Ryom, R. Weber, P. Morlat, C. Pradier et al., Trends in underlying causes of death in people with HIV from, Lancet, vol.384, issue.9939, pp.241-249, 1999.

G. Greub, B. Ledergerber, M. Battegay, P. Grob, L. Perrin et al., Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study, Lancet, vol.356, issue.9244, pp.1800-1805, 2000.

M. M. Kitahata, S. J. Gange, A. G. Abraham, B. Merriman, M. S. Saag et al., Effect of early versus deferred antiretroviral therapy for HIV on survival. The New England journal of medicine, vol.360, pp.1815-1841, 2009.

A. Mocroft, B. Ledergerber, C. Katlama, O. Kirk, P. Reiss et al., Decline in the AIDS and death rates in the EuroSIDA study: an observational study, Lancet, vol.362, issue.9377, pp.22-31, 2003.

L. I. Gjaerde, L. Shepherd, E. Jablonowska, A. Lazzarin, M. Rougemont et al., Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study, 2016.

C. S. Graham, L. R. Baden, Y. E. Mrus, J. M. Carnie, J. Heeren et al., Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, vol.33, pp.562-571, 2001.

R. Sanmartin, J. Tor, A. Sanvisens, J. J. Lopez, A. Jou et al., Progression of liver fibrosis in HIV/ hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. HIV medicine, vol.15, pp.203-215, 2013.

J. M. Molina, C. Orkin, D. M. Iser, F. X. Zamora, M. Nelson et al., Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, nonrandomised, phase 3 study, Lancet, vol.385, issue.9973, pp.62483-62484, 2015.

A. Osinusi, K. Townsend, A. Kohli, A. Nelson, C. Seamon et al., Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection, Jama, vol.313, issue.12, pp.1232-1241, 2015.

L. Piroth, L. Wittkop, K. Lacombe, E. Rosenthal, C. Gilbert et al., Efficacy and safety of directacting antiviral regimens in HIV/HCV-coinfected patients-French ANRS CO13 HEPAVIH cohort

P. Sogni, C. Gilbert, K. Lacombe, L. Piroth, E. Rosenthal et al., All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, vol.63, pp.763-70, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01993207

B. N. Limketkai, S. H. Mehta, C. G. Sutcliffe, Y. M. Higgins, M. S. Torbenson et al., Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV, Jama, vol.308, issue.4, pp.370-378, 2012.

. Lo-re-v-3rd, M. J. Kallan, J. P. Tate, J. K. Lim, M. B. Goetz et al., Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. Open forum infectious diseases, vol.2, 2015.

M. G. Peters, P. Bacchetti, R. Boylan, A. L. French, P. C. Tien et al., Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV, Aids, vol.30, issue.5, pp.723-732, 2015.

J. Berenguer, J. Alvarez-pellicer, P. M. Martin, J. Lopez-aldeguer, M. A. Von-wichmann et al., Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus, Hepatology, vol.50, issue.2, pp.407-420, 2009.

J. Berenguer, E. Rodriguez, P. Miralles, V. Wichmann, M. A. Lopez-aldeguer et al., Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus, vol.55, pp.728-764, 2012.

J. Berenguer, F. X. Zamora, A. Carrero, M. A. Von-wichmann, M. Crespo et al., Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis, Journal of acquired immune deficiency syndromes, vol.66, issue.3, pp.280-287, 2014.

J. A. Mira, A. Rivero-juarez, L. F. Lopez-cortes, J. A. Giron-gonzalez, F. Tellez et al., Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C viruscoinfected patients with compensated cirrhosis, vol.56, pp.1646-53, 2013.

J. L. Casado, M. A. Esteban, S. Banon, A. Moreno, M. J. Perez-elias et al., Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response. Digestive diseases and sciences, Epub 2015/06/27, vol.60, p.26112991, 2015.

A. Cohort, Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients, Aids, vol.29, issue.14, pp.1821-1851, 2015.

V. De-ledinghen, C. Douvin, A. Kettaneh, M. Ziol, D. Roulot et al., Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients, Journal of acquired immune deficiency syndromes, vol.41, issue.2, pp.175-184, 2006.

M. A. Loko, D. Salmon, P. Carrieri, M. Winnock, M. Mora et al., The French national prospective cohort of patients co-infected with HIV and HCV, ANRS CO13 HEPAVIH): early findings, vol.10, p.303, 2006.
URL : https://hal.archives-ouvertes.fr/pasteur-01070193

P. Schmid, A. Bregenzer, M. Huber, A. Rauch, W. Jochum et al., Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy, PloS one, vol.10, issue.9, 2015.

K. G. Alberti, P. Zimmet, J. Shaw, and I. Group, The metabolic syndrome-a new worldwide definition, Lancet, vol.366, issue.9491, pp.1059-62, 2005.

C. Proust-lima and J. M. Taylor, Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach, Biostatistics, vol.10, issue.3, pp.535-584, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00367752

D. Rizopoulos, JM: An R Package for the Joint Modelling of Longitudinal and Time-to-Event Data, Journal of Statistical Software, vol.35, issue.9, 2010.

R. Sanmartin, E. De-felipe, J. Tor, A. Sanvicens, E. Barluenga et al., Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era. AIDS research and human retroviruses, vol.28, pp.1235-1278, 2012.

A. A. Butt, X. Wang, and C. G. Moore, Effect of hepatitis C virus and its treatment on survival, Hepatology, vol.50, issue.2, pp.387-92, 2009.

N. Qurishi, C. Kreuzberg, G. Luchters, W. Effenberger, B. Kupfer et al., Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection, Lancet, vol.362, issue.9397, pp.1708-1721, 2003.